IL43643A - Method for production of gamma globulin - Google Patents
Method for production of gamma globulinInfo
- Publication number
- IL43643A IL43643A IL43643A IL4364373A IL43643A IL 43643 A IL43643 A IL 43643A IL 43643 A IL43643 A IL 43643A IL 4364373 A IL4364373 A IL 4364373A IL 43643 A IL43643 A IL 43643A
- Authority
- IL
- Israel
- Prior art keywords
- polymer
- block
- final concentration
- supernatant
- retention
- Prior art date
Links
- 108010074605 gamma-Globulins Proteins 0.000 title claims abstract 4
- 238000004519 manufacturing process Methods 0.000 title 1
- 229920001400 block copolymer Polymers 0.000 claims abstract 13
- -1 polyoxypropylene Polymers 0.000 claims abstract 8
- 239000006228 supernatant Substances 0.000 claims abstract 7
- 239000002244 precipitate Substances 0.000 claims abstract 6
- 238000001556 precipitation Methods 0.000 claims abstract 6
- 230000002209 hydrophobic effect Effects 0.000 claims abstract 5
- 229920001451 polypropylene glycol Polymers 0.000 claims abstract 5
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims abstract 4
- 108010039209 Blood Coagulation Factors Proteins 0.000 claims abstract 3
- 102000015081 Blood Coagulation Factors Human genes 0.000 claims abstract 3
- 239000003114 blood coagulation factor Substances 0.000 claims abstract 3
- 229910000389 calcium phosphate Inorganic materials 0.000 claims abstract 2
- 239000001506 calcium phosphate Substances 0.000 claims abstract 2
- 235000011010 calcium phosphates Nutrition 0.000 claims abstract 2
- 238000002156 mixing Methods 0.000 claims abstract 2
- 239000002504 physiological saline solution Substances 0.000 claims abstract 2
- 239000007858 starting material Substances 0.000 claims abstract 2
- 238000007864 suspending Methods 0.000 claims abstract 2
- 239000000725 suspension Substances 0.000 claims abstract 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims abstract 2
- 238000000034 method Methods 0.000 claims 6
- 230000014759 maintenance of location Effects 0.000 claims 5
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 3
- 235000008504 concentrate Nutrition 0.000 claims 2
- 239000012141 concentrate Substances 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 102000009027 Albumins Human genes 0.000 abstract 1
- 108010088751 Albumins Proteins 0.000 abstract 1
- 108010032597 Cohn fraction II Proteins 0.000 abstract 1
- 108010044091 Globulins Proteins 0.000 abstract 1
- 102000006395 Globulins Human genes 0.000 abstract 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 abstract 1
- 239000000047 product Substances 0.000 abstract 1
- 230000000717 retained effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
1435816 Obtaining gamma globulin BAXTER LABORATORIES INC 26 Nov 1973 [27 Nov 1972] 54703/73 Heading A5B A water-soluble, intravenously administrable y-globulin is prepared by suspending whole plasma or any of Cohn Plasma Fractions II, II+III and III in normal physiological saline, adjusting the pH to 6.5 to 7.5, mixing the suspension with calcium phosphate to absorb coagulation factors, removing the precipitate and subjecting the supernatant to three successive precipitations by addition of a watersoluble block copolymer of ethylene oxide and propylene oxide comprising at least 50% ethylene oxide and having a polyoxypropylene hydrophobic base molecular weight of at least 950, the first at a pH of 4 to 5 with a final concentration of 6 to 8.5% block copolymer; the second at a pH of 4.5 to 5.5 and a final concentration 8.5% to 10%, and the third at a pH of 6.5 to 7.5 and a final concentration of 14 to 16%, the supernatant from the first two precipitations being retained and the third precipitate being the required product. If whole plasma Cohn Fraction II+III are used, the starting material is preferably subjected to an initial precipitation step at pH 6.5 to 7.5 to a concentration of 12 to 16% to remove albumin which remains in the supernatant whilst the globulins are precipitated.
[GB1435816A]
Claims (6)
1. The method of preparing a highly soluble gamma globulin concentrate suitable for intravenous administration comprising sus - pending material selected from the group consisting of whole plasma and any of Cohn Plasma Fractions 11 + ΙΠ, II and III in normal physio- logical saline, adjusting the pH to about 6. 5 to 7. 5, mixing the sus- pension with calcium phosphate to adsorb the coagulation factors, separating the resulting precipitate and subjecting the recovered supernatant to a succession of three precipitations with a block co-polymer of ethylene oxide and polyoxypropylene polymer containing at least about 50% ethylene oxide in the molecule and a polyoxypropylene hydrophobic base molecular weight of at least about 950, first at a pH of about 4 to 5 and a final concentration of about 6. 0% to 8. 5% block co-polymer with retention of the resulting supernatant for the succeed-ing step, then at a pH of about 4. 5 to 5. 5 and a final concentration of above 8. 5% to about 10% block co -polymer with retention of the result -ing supernatant for the succeeding step and then at a pH of about 6. 5 to 7. 5 and a final concentration of about 14% to 16% block co-polymer with retention of the resulting precipitate as the active gamma globulin con-centrate.
2. The method of Claim 1 in which the block co-polymer con-tains about 80% of polyoxyethylene hydrophilic units in the molecule and the polyoxypropylene hydrophobic base has a molecular weight of 950.
3. The method of Claim 1 including the additional step of sub-jecting the supernatant separated from the adsorbed coagulation factors to an initial precipitation with said block co-polymer at a pH of about 6. 5 to 7. 5 and a final concentration of about 12% to 16% block co-polymer with retention of the resulting precipitate for the succeeding step.
4. The method of Claim 3 in which the block co-polymer contains about 80% of polyoxyethylene hydrophilic units in the mole-cule and the polyoxypropopylene hydrophobic base has a molecular weight of 950.
5. The method of Claim 3 in which the starting material is whole plasma including the additional step of subjecting said whole plasma to an initial precipitation with said block co-polymer at a pH of about 6. 5 to 7. 5 to a final concentration of about 13% to 16% block co-polymer with retention of the resulting precipitate for the succeeding step.
6. The method of Claim 5 in which the block co-polymer contains about 80% of polyoxyethylene hydrophilic units in the mole-cule and the polyoxypropylene hydrophobic base has a molecular weight of 950. For to* Applicants
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30984172A | 1972-11-27 | 1972-11-27 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL43643A0 IL43643A0 (en) | 1974-03-14 |
| IL43643A true IL43643A (en) | 1976-10-31 |
Family
ID=23199896
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL43643A IL43643A (en) | 1972-11-27 | 1973-11-16 | Method for production of gamma globulin |
Country Status (16)
| Country | Link |
|---|---|
| JP (1) | JPS5843371B2 (en) |
| AT (1) | AT325208B (en) |
| AU (1) | AU6265873A (en) |
| BE (1) | BE807527A (en) |
| CA (1) | CA1016069A (en) |
| DE (1) | DE2357800A1 (en) |
| DK (1) | DK135270B (en) |
| ES (1) | ES420846A1 (en) |
| FR (1) | FR2207698B1 (en) |
| GB (1) | GB1435816A (en) |
| IL (1) | IL43643A (en) |
| IT (1) | IT1196391B (en) |
| NL (1) | NL7315859A (en) |
| NO (1) | NO137861C (en) |
| SE (1) | SE390795B (en) |
| ZA (1) | ZA738779B (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2364792A1 (en) * | 1973-01-15 | 1974-07-18 | South African Inventions | Gamma-Globulin purification - by precipitating impurities with uncharged polymers at pH 4-5 |
| DE2500076C3 (en) * | 1975-01-02 | 1982-11-18 | SCHURA Blutderivate GmbH & Co KG, 4150 Krefeld | Process for the production of intravenously tolerated gamma globulins |
| US4057628A (en) * | 1976-04-19 | 1977-11-08 | William L. Wilson | Removal of hepatitis associated antigen from plasma |
| JPS6016406B2 (en) * | 1976-08-06 | 1985-04-25 | マイヤ−、ル−イス、コ−バル | Method for producing intravenously administrable gamma globulin and gamma globulin prepared thereby |
| JPS5347515A (en) * | 1976-10-13 | 1978-04-28 | Green Cross Corp:The | Gamma-globulin pharmaceutical preparation for intravenous injection |
| US4124576A (en) * | 1976-12-03 | 1978-11-07 | Coval M L | Method of producing intravenously injectable gamma globulin |
| US4272521A (en) * | 1979-07-16 | 1981-06-09 | Cutter Laboratories, Inc. | Purified immune serum globulin |
| JPS5732228A (en) * | 1980-08-05 | 1982-02-20 | Green Cross Corp:The | Preparation of immunoglobulin usable for intravenous injection |
| EP0078331B1 (en) * | 1981-10-29 | 1986-01-29 | Green Cross Corporation | Process for preparing immunoglobulin suitable for intravenous injection |
| JPS58180433A (en) * | 1982-04-16 | 1983-10-21 | Fujirebio Inc | Method for removing anti-complement agents from immunoglobulins |
-
1973
- 1973-11-16 ZA ZA738779A patent/ZA738779B/en unknown
- 1973-11-16 IL IL43643A patent/IL43643A/en unknown
- 1973-11-19 AU AU62658/73A patent/AU6265873A/en not_active Expired
- 1973-11-20 BE BE137926A patent/BE807527A/en unknown
- 1973-11-20 DE DE2357800A patent/DE2357800A1/en not_active Ceased
- 1973-11-20 NL NL7315859A patent/NL7315859A/xx not_active Application Discontinuation
- 1973-11-21 IT IT31571/73A patent/IT1196391B/en active
- 1973-11-23 DK DK635573AA patent/DK135270B/en unknown
- 1973-11-26 JP JP48132524A patent/JPS5843371B2/en not_active Expired
- 1973-11-26 GB GB5470373A patent/GB1435816A/en not_active Expired
- 1973-11-26 NO NO4490/73A patent/NO137861C/en unknown
- 1973-11-26 AT AT987973A patent/AT325208B/en not_active IP Right Cessation
- 1973-11-26 SE SE7315988A patent/SE390795B/en unknown
- 1973-11-26 FR FR7341980A patent/FR2207698B1/fr not_active Expired
- 1973-11-26 ES ES420846A patent/ES420846A1/en not_active Expired
- 1973-11-26 CA CA186,705A patent/CA1016069A/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| GB1435816A (en) | 1976-05-19 |
| JPS4981519A (en) | 1974-08-06 |
| AU6265873A (en) | 1975-05-22 |
| FR2207698A1 (en) | 1974-06-21 |
| DK135270B (en) | 1977-03-28 |
| NO137861C (en) | 1978-05-10 |
| IL43643A0 (en) | 1974-03-14 |
| ES420846A1 (en) | 1976-06-16 |
| ZA738779B (en) | 1974-10-30 |
| NO137861B (en) | 1978-03-30 |
| DE2357800A1 (en) | 1974-06-06 |
| FR2207698B1 (en) | 1976-09-03 |
| DK135270C (en) | 1977-09-19 |
| IT1196391B (en) | 1988-11-16 |
| SE390795B (en) | 1977-01-24 |
| NL7315859A (en) | 1974-05-29 |
| JPS5843371B2 (en) | 1983-09-27 |
| BE807527A (en) | 1974-03-15 |
| CA1016069A (en) | 1977-08-23 |
| AT325208B (en) | 1975-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US3763135A (en) | Gamma globulin production from cohn fraction iii using polyethylene glycol | |
| US4880913A (en) | Process for the preparation of an immunoglobulin which can be administered intravenously and is stable in liquid form | |
| Korngold et al. | The localization of antilymphosarcoma antibodies in the Murphy lymphosarcoma of the rat | |
| RU2311460C2 (en) | Method of purifying lipopeptide (options) amd antibiotic composition based on purified lipopeptide (options) | |
| Melmon et al. | Receptors for histamine can be detected on the surface of selected leukocytes | |
| IL43643A (en) | Method for production of gamma globulin | |
| US4165370A (en) | Injectable gamma globulin | |
| CA1074698A (en) | Method of collecting anti-hemophilic factor viii from blood and blood plasma | |
| US3869436A (en) | Method for fractionating plasma proteins using peg and ion-exchangers | |
| HU182554B (en) | Process for producing preparation of serum protein for intravenous application | |
| US3808189A (en) | Isolation of gamma globulin preparations enriched in iga and igm using polyethylene glycol | |
| CA1243950A (en) | Process for producing a high purity antihemophilic factor concentrate | |
| US4164495A (en) | Method of recovering immunoglobulin using a polyol and an alkanoic acid | |
| US5250662A (en) | Albumin purification | |
| IE43449B1 (en) | Process reducing the anticomplementary activity of gamma globulins | |
| AU2013231321A1 (en) | Improved process for production of fibrinogen and fibrinogen produced thereby | |
| USRE31268E (en) | Method of recovering immunoglobulin using a polyol and an alkanoic acid | |
| Teisner et al. | Factor I deficiency and C3 nephritic factor: immunochemical findings and association with Neisseria meningitidis infection in two patients | |
| US4835257A (en) | Process for preparing gamma globulin suitable for intravenous administration using peg and a citrate buffer | |
| Bjerrum et al. | An immunochemical approach for the analysis of membrane protein alterations in Ca2+‐loaded human erythrocytes | |
| US3925152A (en) | Virus separation | |
| EP0422769B1 (en) | Albumin purification | |
| US4302445A (en) | Method for concentrating and purifying antihemophilic factor or factor VIII | |
| GB1436529A (en) | Process for preparing a blood fraction | |
| Clark et al. | Further studies on the purification of poliomyelitis virus |